GTBP

Business Context and Reporting Period

Company: OXIS International, Inc. (Note: Input metadata referenced "GT Biopharma," but the filing text identifies the registrant as OXIS International, Inc.)
Reporting Period: Quarter ended March 31, 2011
Business Overview: OXIS is a smaller reporting company engaged in the research, development, and sale of products targeting oxidative stress and inflammation. Its primary focus is on L-Ergothioneine ("ERGO") based nutraceuticals, cosmeceuticals, and functional foods. The company operates in a single reportable segment.

Key Financial Metrics

Liquidity Position: The company reported a working capital deficit of approximately $7.065 million on a cash basis. Cash balances dropped from $54,000 at the beginning of the quarter to $1,000 at period end.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $20,000 in product revenue from a direct mail test market for "ErgoFlex," compared to zero revenue in the prior year. However, the cost of product revenue ($25,000) exceeded sales, resulting in a gross loss of $5,000 due to high start-up manufacturing costs.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly to $1,832,000 from $925,000 in Q1 2010. This increase is attributed to higher non-cash compensation, overhead, independent contractor fees, and shareholder relations expenses.
• Derivative Liabilities: The company recognized a gain of $103,000 from the change in value of warrant and derivative liabilities, contrasting with a $773,000 loss in the same period in 2010.
• Debt Conversions: Significant debt was converted into equity during the quarter. Approximately 20.2 million shares of common stock were issued to retire debt valued at $229,000.

Outlook, Risks, and Management Commentary

Going Concern: Management explicitly states that the current rate of cash usage raises substantial doubt about the company's ability to continue as a going concern. With only $1,000 in cash and significant current liabilities, the company intends to seek additional equity or debt financing to sustain operations.

Strategic Initiatives:

• Joint Venture: Signed a term sheet on March 1, 2011, with Engage:BDR to form a joint venture for online marketing. OXIS is required to contribute up to $1.5 million in the first year, though operations have not yet commenced.
• Capitalization: In January 2011, the company amended its Certificate of Incorporation to increase authorized common stock to 600 million shares to accommodate outstanding options, warrants, and convertible debentures.

Risks and Contingencies:

• Debt Defaults: The company is in default on monthly redemption payments for convertible debentures issued in 2006. Holders have the right to accelerate repayment and sell company assets.
• Financing Uncertainty: There is no assurance that the company will successfully obtain the necessary funding to fund the joint venture or repay current liabilities.
• Dilution: Future financing or debt conversions will likely result in significant dilution to existing shareholders.

Investor Verification Checklist

• Cash Runway: Verify the immediate status of the $1,000 cash balance and any new financing secured post-filing to address the working capital deficit.
• Debt Default Status: Confirm the current standing of the 2006 convertible debentures and whether holders have initiated foreclosure or asset sales.
• Joint Venture Funding: Assess the company's ability to fund the required $1.5 million contribution to the Engage:BDR joint venture without additional capital raises.
• Revenue Sustainability: Evaluate whether the $20,000 in Q1 revenue is a one-time test market result or indicative of scalable sales.
• Share Count: Monitor the impact of the 600 million authorized shares and the high volume of outstanding warrants and options on future dilution.